2. Search Result
Search Result
Results for "

Gly13

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

1

Biochemical Assay Reagents

9

Peptides

9

Isotope-Labeled Compounds

4

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153724
    BI-2865
    Maximum Cited Publications
    11 Publications Verification

    		 Ras Cancer
    BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively. BI-2865 inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 cells (mean IC50: roughly 140 nM) .
    BI-2865
  • HY-173632
    AMG410

    		Ras Cancer
    AMG410 is a non-covalent and selective pan-KRAS inhibitor with IC50 values of 1-4 nM for KRAS G12D, KRAS G12V, and KRAS G13D. AMG410 shows greater than 100-fold selectivity against both HRAS and NRAS. AMG410 is a dual GTP(on)- and GDP(off)-state inhibitor (Kd(GDP-state) of 1 nM; Kd(GTP-state) of 22 nM). AMG410 blocks KRAS signaling in a cycling state-independent manner and also blocks proliferation in wildtype KRAS-amplified tumor cells. AMG410 can be used for the study of colorectal, pancreatic, and lung cancers .
    AMG410
  • HY-15610
    GDC-0623
    5+ Cited Publications

    RG 7421; MEK inhibitor 1

    		 MEK Apoptosis Cancer
    GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAF V600E, EC50=7 nM).
    GDC-0623
  • HY-176954
    RSC-1255

    		Proton Pump Ras Autophagy Apoptosis Cancer
    RSC-1255 is a potent and selective Vacuolar H⁺-ATPase (V-ATPase) inhibitor that directly binds the mammalian V-ATPase complex with a Kd = 23 nM. RSC-1255 exhibits preferential cytotoxicity toward KRAS-mutant cancer cells, especially KRAS G13D and KRAS G12V cells. RSC-1255 induces apoptosis and blocks lysosomal acidification, autophagy, and macropinocytosis in cancer cells. RSC-1255 can be used for the study of KRAS-driven lung and colon cancers .
    RSC-1255
  • HY-144661
    KRAS G12D inhibitor 14

    		Ras Apoptosis Cancer
    KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a KD of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D .
    KRAS G12D inhibitor 14
  • HY-176785S
    MCB-294

    		Ras Apoptosis p38 MAPK Caspase TNF Receptor Cancer
    MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRAS G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer .
    MCB-294
  • HY-109589A
    trans-11-Eicosenoic acid
    1 Publications Verification

    		 Phosphatase Bacterial Infection
    trans-11-Eicosenoic acid is a fatty acid that inhibits the phosphatase activity of PtpA from Mycobacterium tuberculosis, with an IC50 of 27.97 µM. trans-11-Eicosenoic acid is detected in the stems of alfalfa plants inoculated with Sinorhizobium meliloti LL11, but is absent in the stems of uninoculated alfalfa or the strain itself .
    trans-11-Eicosenoic acid
  • HY-156529
    pan-KRAS-IN-2

    		Ras Cancer
    pan-KRAS-IN-2 (Compound 6) is a pan-inhibitor with IC50s ≤ 10 nM for KRAS WT and mutants (G12D, G12C, G12V, G12S, G12A and Q61H); and an IC50 > 10 μM for KRAS G13D. pan-KRAS-IN-2 can be used to study various KRAS-mediated cancers, such as pancreatic cancer and colorectal cancer .
    pan-KRAS-IN-2
  • HY-176489
    PROTAC pan-KRAS degrader-1

    		PROTACs Ras Cancer
    PROTAC pan-KRAS degrader-1 is a pan-KRAS PROTAC degrader for degrading different KRAS mutation types, such as G12D, G12C, G12V, and G13D. PROTAC pan-KRAS degrader-1 potently degrades KRAS mutation (G12D) in AGS cells, with a DC50 of 1.1 nM, Dmax of 95%. PROTAC pan-KRAS degrader-1 can be used to search diseases caused by KRAS mutation or amplification, especially cancers such as breast cancer, bladder cancer, gastric cancer, etc . Pink: pan-KRAS ligand (HY-176490); Blue: VHL ligase ligand (HY-170353); Black: linker (HY-176491);
    PROTAC pan-KRAS degrader-1
  • HY-145962A
    MRTX-EX185 formic

    		Ras Cancer
    MRTX-EX185 formic is a potent KRAS (G12D) inhibitor with an IC50 of 90 nM. MRTX-EX185 formic can binds both GDP-loaded and active GNP states of KRAS and KRAS (G12D). MRTX-EX185 formic exhibits broad-spectrum binding properties with IC50s of 110, 290, 130 and 240 nM for KRAS WT, KRAS (G12C), KRAS (Q61H), KRAS (G13D). MRTX-EX185 formic also binds GDP-loaded HRAS. MRTX-EX185 formic can be used to study various RAS-driven tumors (such as pancreatic cancer) .
    MRTX-EX185 formic
  • HY-159591
    YK-8S

    		Ras Akt ERK Cancer
    YK-8S is a dual-targeted K-Ras (G12D/G12C) covalent inhibitor. YK-8S shows no significant binding to wild-type K-Ras and other mutants (G12R, G13D, Q61R/K). YK-8S exhibits anti-proliferative activity against H358 (G12C) and AGS (G12D) cells. YK-8S inhibits the phosphorylation of p-AKT/p-ERK in BaF3/G12D and G12C cells. YK-8S can be used for pancreatic cancer, colorectal cancer and other tumors with high incidence of G12D .
    YK-8S
  • HY-161066
    KRAS G13D-IN-1

    		Ras Cancer
    KRAS G13D-IN-1 (Compound 41) is a selective and covalently reversible inhibitor of KRAS G13D (IC50: 0.41 nM). The selectivity for KRAS G13D is 29-fold against KRAS wild type. KRAS G13D-IN-1 is an inhibitor of the GDP state and targets the SWII binding pocket of KRAS G13D. KRAS G13D-IN-1 inhibits KRAS binding to GDP and turns on/off downstream signaling cascades. KRAS G13D-IN-1 can be used in the research of colon cancer .
    KRAS G13D-IN-1
  • HY-145962
    MRTX-EX185

    		Ras Cancer
    MRTX-EX185 is a potent KRAS (G12D) inhibitor with an IC50 of 90 nM. MRTX-EX185 can binds both GDP-loaded and active GNP states of KRAS and KRAS (G12D). MRTX-EX185 exhibits broad-spectrum binding properties with IC50s of 110, 290, 130 and 240 nM for KRAS WT, KRAS (G12C), KRAS (Q61H), KRAS (G13D). MRTX-EX185 also binds GDP-loaded HRAS. MRTX-EX185 can be used to study various RAS-driven tumors (such as pancreatic cancer) .
    MRTX-EX185
  • HY-178497
    ZJK-807

    		PROTACs Ras p38 MAPK TNF Receptor Inflammation/Immunology Cancer
    ZJK-807 is a highly effective and selective PROTAC degrader targeting KRASG12D (DC50 = 79.5 nM in AsPC-1 cells). ZJK-807 shows minimal impact on wild-type KRAS or other mutants (G12C/S/V, G13D), inducing mutant-specific cytotoxicity. ZJK-807 suppresses RAS/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis. ZJK-807 can be used for the study of KRAS-driven pancreatic cancer. Yellow: KRASG12D ligand (HY-W087383); Green: E3 ligase CRBN ligand (HY-178507); Black: Linker (HY-178506) .
    ZJK-807
  • HY-179452
    KRAS G13D-IN-2

    		Ras CDK Mitochondrial Metabolism Cancer
    KRAS G13D-IN-2 (compound 8B) is a potent orally active KRAS G13D inhibitor with IC50 values of 1.95 μM (HCT-116 G13D) and 2.16 μM (HCT-15 G13D). KRAS G13D-IN-2 induces G1-phase arrest and mitochondrial membrane depolarization. KRAS G13D-IN-2 induces senescence through CDK6/TWIST1 inhibition. KRAS G13D-IN-2 inhibits tumor growth in murine models. KRAS G13D-IN-2 can be used for KRAS G13D-mutant colorectal cancer research .
    KRAS G13D-IN-2
  • HY-P2064
    Lariatin A

    		Bacterial Infection
    Lariatins is a novel anti-mycobacterial peptides with a lasso structure produced by Rhodococcus jostii K01-B0171 .
    Lariatin A
  • HY-P3129
    KRAS G13D peptide, 25 mer

    		Ras Inflammation/Immunology Cancer
    KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine .
    KRAS G13D peptide, 25 mer
  • HY-179536
    KRAS-IN-49

    		Ras Cancer
    KRAS-IN-49 (compound 7b) is a selective and covalent KRAS G13C inhibitor. KRAS-IN-49 covalently binds to Cys13 of KRAS G13C. KRAS-IN-49 can be used for non-small cell lung cancer (NSCLC) research .
    KRAS-IN-49
  • HY-176176S
    MDEKMLVLWVVALS(Gly-13C2,15N)IST

    		Isotope-Labeled Compounds Others
    MDEKMLVLWVVALS(Gly- 13C2, 15N)IST is the 13C- and 15N-labeled MDEKMLVLWVVALSIST.
    MDEKMLVLWVVALS(Gly-13C2,15N)IST
  • HY-159193S
    DHATS(Leu-13C6,15N)PVTIPSAVST(Gly-13C2,15N)HTTPLPVTDT TFA

    		Isotope-Labeled Compounds Others
    DHATS(Leu- 13C6, 15N)PVTIPSAVST(Gly- 13C2, 15N)HTTPLPVTDT (TFA) is the 13C and 15N labeled isotope of DHATS-PVTIPSAVST-HTTPLPVTDT (TFA) .
    DHATS(Leu-13C6,15N)PVTIPSAVST(Gly-13C2,15N)HTTPLPVTDT TFA
  • HY-W777099
    N-Cbz-O-Bzl-L-Glu-S-Bzl-L-Cys-Gly[13C2,15N]-OBzl

    		Isotope-Labeled Compounds Others
    N-Cbz-O-Bzl-L-Glu-S-Bzl-L-Cys-Gly[ 13C2, 15N]-OBzl is the 13C- and 15N-labeled N-Cbz-O-Bzl-L-Glu-S-Bzl-L-Cys-Gly-OBzl.
    N-Cbz-O-Bzl-L-Glu-S-Bzl-L-Cys-Gly[13C2,15N]-OBzl
  • HY-P0206S1
    RPP-(Gly-13C2,15N)-FSPFR TFA

    		Isotope-Labeled Compounds Bradykinin Receptor Endogenous Metabolite Ser/Thr Protease Cardiovascular Disease Endocrinology
    RPP-(Gly-1 13C2, 15N)-FSPFR TFA is 13C- and 15N-labeled Bradykinin (HY-P0206). Bradykinin is an effective endothelium-dependent vasodilator that can lower blood pressure. Bradykinin can induce contraction of bronchial and intestinal non-vascular smooth muscle, increase vascular permeability, and participate in the mechanism of pain .
    RPP-(Gly-13C2,15N)-FSPFR TFA
  • HY-P10135
    RES-701-1

    		Endothelin Receptor Cardiovascular Disease
    RES-701-1 is a cyclic peptide composed of 16 common L-amino acids, acting as a specific antagonist for the ETB receptor. RES-701-1 can inhibit the binding of 125I-ET-1 (125I-labeled Endothelin (ET)-1) to the ETB receptor, with an IC50 value of 10 nM .
    RES-701-1
  • HY-P1432A
    K-(D-1-Nal)-FwLL-NH2 TFA

    		GHSR Cancer
    K-(D-1-Nal)-FwLL-NH2 TFA is a high affinity and potent ghrelin receptor inverse agonist (Ki values are 4.9 and 31 nM in COS7 and HEK293T cells, respectively). K-(D-1-Nal)-FwLL-NH2 blocks ghrelin receptor-mediated Gq- and G13-dependent signaling pathways.
    K-(D-1-Nal)-FwLL-NH2 TFA
  • HY-137638
    Sp-5,6-DCl-cBIMPS

    		PKA Metabolic Disease
    Sp-5,6-DCl-cBIMPS is a potent and specific cAMP-dependent protein kinases (cAMP-PK) activator. Sp-5,6-DCl-cBIMPS stimulates insulin release. Sp-5,6-DCl-cBIMPS inhibits U-46619 (HY-108566)-induced activation of Rho, Gq and G12/G13 in platelets .
    Sp-5,6-DCl-cBIMPS
  • HY-137638A
    Sp-5,6-DCl-cBIMPS sodium

    Sp-5,6-DCI-cBIMPS

    		 PKA Metabolic Disease
    Sp-5,6-DCl-cBIMPS sodium is a potent and specific cAMP-dependent protein kinases (cAMP-PK) activator. Sp-5,6-DCl-cBIMPS sodium stimulates insulin release. Sp-5,6-DCl-cBIMPS sodium inhibits U-46619 (HY-108566)-induced activation of Rho, Gq and G12/G13 in platelets .
    Sp-5,6-DCl-cBIMPS sodium
  • HY-162873
    MEK/RAF-IN-1

    		MEK Raf Cancer
    MEK/RAF-IN-1 (Compound 16b) is an inhibitor of both MEK and RAF. It shows potent inhibition with IC50 values of 28 nM for MEK1, and 3 nM each for BRAF and BRAFV600E. MEK/RAF-IN-1 demonstrates significant antitumor activity, effectively inhibiting cell proliferation in vitro against MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Additionally, it inhibits tumor growth in xenograft mouse models of colorectal cancer .
    MEK/RAF-IN-1
  • HY-173349
    TDI-012804

    		PARP Cancer
    TDI-012804 is a TNKS2 inhibitor that selectively inhibits intracellular endogenous TNKS2 protein. TDI-012804 increases the expression of AXIN1 protein in cells that are heterozygous (Tnks1HET) and completely knocks out (Tnks1KO) for TNKS1. TDI-012804 inhibits the proliferation of ApcQ1405X/Tnks1KO organoids (EC50 of 59.1 nM) and is selectively toxic to Tnks1KO AKP-G12D and AKP-G13D organoids .
    TDI-012804
  • HY-179534
    G13Ci-22

    		Ras Cancer
    G13Ci-22 is a MRTX1133 (HY-134813) based KRAS G13C inhibitor. G13Ci-22 can be used for non-small cell lung cancer (NSCLC) research .
    G13Ci-22
  • HY-P0073S1
    Tyr-{Gly-13C2,15N}-Gly-Phe-Met-OH TFA

    Met-Enkephalin-13C2,15N TFA; Methionine enkephalin-13C2,15N TFA; Metenkefalin-13C2,15N TFA

    		 Isotope-Labeled Compounds Opioid Receptor Neurological Disease Cancer
    Tyr-{Gly- 13C2, 15N}-Gly-Phe-Met-OH TFA (Met-Enkephalin- 13C2, 15N TFA) is the 13C- and 15N-labeled Tyr-Gly-Gly-Phe-Met-OH TFA. Tyr-Gly-Gly-Phe-Met-OH regulates human immune function and inhibits tumor growth via binding to the opioid receptor.
    Tyr-{Gly-13C2,15N}-Gly-Phe-Met-OH TFA
  • HY-P0073S2
    Tyr-Gly-{Gly-13C2,15N}-Phe-Met-OH TFA

    Met-Enkephalin-13C2,15N TFA-1; Methionine enkephalin-13C2,15N TFA-1; Metenkefalin-13C2,15N TFA-1

    		 Isotope-Labeled Compounds Opioid Receptor Neurological Disease Cancer
    Tyr-Gly-{Gly- 13C2, 15N}-Phe-Met-OH TFA (Met-Enkephalin- 13C2, 15N TFA-1) is the 13C- and 15N-labeled Tyr-Gly-Gly-Phe-Met-OH TFA. Tyr-Gly-Gly-Phe-Met-OH regulates human immune function and inhibits tumor growth via binding to the opioid receptor.
    Tyr-Gly-{Gly-13C2,15N}-Phe-Met-OH TFA
  • HY-176353S
    KRAS 2B G13C mutant, Arg-13C6,15N4, Lys-13C6,15N2

    		Isotope-Labeled Compounds Cancer
    KRAS 2B G13C mutant, Arg- 13C36, 15N4, Lys- 13C6, 15N2 is the 13C- and 15N-labeled KRAS 2B G13C mutant.
    KRAS 2B G13C mutant, Arg-13C6,15N4, Lys-13C6,15N2
  • HY-176341S
    KRAS 2B G13D mutant, Arg-13C6,15N4, Lys-13C6,15N2

    		Isotope-Labeled Compounds Cancer
    KRAS 2B G13D mutant, Arg-Arg- 13C36, 15N4, Lys- 13C6, 15N2 is the 13C- and 15N-labeled KRAS 2B G13D mutant.
    KRAS 2B G13D mutant, Arg-13C6,15N4, Lys-13C6,15N2
  • HY-186086
    RM-041

    		Ras Cancer
    RM-041 is a selective, orally active KRAS G13C (ON) inhibitor that forms a covalent complex with KRAS G13C (ON) and Cyclophilin A. RM-041 blocks the binding of RAS effector proteins via steric hindrance, and then covalently binds to Cys-13 to form an irreversible inhibitory complex, thereby inhibiting the proliferation of KRAS G13C mutant cancer cells. RM-041 induces regression of KRAS G13C tumors in cellular and xenograft tumor models. RM-041 exerts a synergistic effect when combined with upstream node inhibitors (such as SHP2 inhibitors). RM-041 can be used for the research of non-small cell lung cancer .
    RM-041
  • HY-172215
    PPO-IN-18

    		Herbicide Protoporphyrinogen IX oxidase Others
    PPO-IN-18 (Compound g13) is the inhibitor for protoporphyrinogen oxidase (PPO) that inhibits Echinochloa crus-galli PPO (EcPPO) with an IC50 of 0.109 μM. PPO-IN-18 exhibits herbicidal effect against E. crus-galli, Digitaria sanguinalis, Setaria faberi, Ipomoea nil, Chenopodium quinoa, and Abutilon theophrasti, without significant toxicity in crops (150-300 g ai/ha) .
    PPO-IN-18
  • HY-181704
    KRAS-IN-54

    		PERK Ras Cancer
    KRAS-IN-54 is a macrocyclic KRAS inhibitor. KRAS-IN-54 exhibits activity against cell viability and pERK inhibition in cells with KRAS G12D and KRAS G13D mutations. KRAS-IN-54 can be used in the research of KRAS-mutant cancers, including pancreatic adenocarcinoma, colorectal cancer, non-small cell lung cancer, esophageal cancer, gallbladder cancer, melanoma, ovarian cancer and endometrial cancer .
    KRAS-IN-54
  • HY-173632A
    AMG410 diTFA

    		Ras Cancer
    AMG410 diTFA is a non-covalent and selective pan-KRAS inhibitor with IC50 values of 1-4 nM for KRAS G12D, KRAS G12V, and KRAS G13D. AMG410 diTFA shows greater than 100-fold selectivity against both HRAS and NRAS. AMG410 diTFA is a dual GTP(on)- and GDP(off)-state inhibitor (Kd(GDP-state) of 1 nM; Kd(GTP-state) of 22 nM). AMG410 diTFA blocks KRAS signaling in a cycling state-independent manner and also blocks proliferation in wildtype KRAS-amplified tumor cells. AMG410 diTFA can be used for the study of colorectal, pancreatic, and lung cancers .
    AMG410 diTFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: